Dyax Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 203

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $6.5B

Dyax General Information

Description

Developer of biopharmaceuticals for oncology and inflammatory indications. The company offers drug discovery technology, known as phage display to identify antibody, small protein and peptide compounds for clinical development and provides chromatography separations systems and products that are used in laboratories and pharmaceutical manufacturing to separate molecules in liquid mixtures.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 55 Network Drive
  • Burlington, MA 01803
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 55 Network Drive
  • Burlington, MA 01803
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dyax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 22-Jan-2016 $6.5B Completed Generating Revenue
11. PIPE 02-Nov-2015 Completed Generating Revenue
10. PIPE 13-May-2013 Completed Generating Revenue
9. PIPE 01-Jan-2012 Completed Generating Revenue
8. PIPE 01-Jan-2009 Completed Generating Revenue
7. PIPE 01-Oct-2008 Completed Generating Revenue
6. PIPE 01-Aug-2006 Completed Generating Revenue
5. PIPE 14-Mar-2003 Completed Generating Revenue
4. IPO 15-Aug-2000 $60M $104M Completed Generating Revenue
3. Later Stage VC 16-Nov-1998 $31M $44.5M Completed Startup
To view Dyax’s complete valuation and funding history, request access »

Dyax Patents

Dyax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022076835-A1 Methods and apparatuses for modeling adamts13 and von willebrand factor interactions Inactive 09-Oct-2020
WO-2021202948-A2 Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome Inactive 04-Apr-2020
WO-2021202948-A3 Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome Inactive 04-Apr-2020
US-12528880-B2 Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack Active 13-Jan-2020
US-20230192889-A1 Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack Active 13-Jan-2020 C07K16/40
To view Dyax’s complete patent history, request access »

Dyax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dyax Former Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Baker Brothers Investments Hedge Fund Minority
BancBoston Capital PE/Buyout Minority
BancBoston Ventures Venture Capital Minority
Federated Investors and Affiliates Corporation Minority
You’re viewing 5 of 27 investors. Get the full list »

Dyax ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Dyax’s complete esg history, request access »

Dyax FAQs

  • When was Dyax founded?

    Dyax was founded in 1995.

  • Where is Dyax headquartered?

    Dyax is headquartered in Burlington, MA.

  • What is the size of Dyax?

    Dyax has 203 total employees.

  • What industry is Dyax in?

    Dyax’s primary industry is Drug Discovery.

  • Is Dyax a private or public company?

    Dyax is a Private company.

  • What is the current valuation of Dyax?

    The current valuation of Dyax is .

  • What is Dyax’s current revenue?

    The current revenue for Dyax is .

  • How much funding has Dyax raised over time?

    Dyax has raised $193M.

  • Who are Dyax’s investors?

    Alta Partners, Baker Brothers Investments, BancBoston Capital, BancBoston Ventures, and Federated Investors and Affiliates are 5 of 27 investors who have invested in Dyax.

  • When was Dyax acquired?

    Dyax was acquired on 22-Jan-2016.

  • Who acquired Dyax?

    Dyax was acquired by Shire (Pharmaceuticals).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process